Prevalence of Hepatic Steatosis and Fibrosis in Cushing's Syndrome

What this Trial Is About

Cushing's Syndrome is a rare condition caused by prolonged high levels of cortisol in the body. Many patients experience metabolic issues such as abdominal obesity, insulin resistance, abnormal blood fats, and high blood pressure. Excess cortisol may also lead to fat buildup in the liver, but little data exists in humans about this effect. Non-Alcoholic Fatty Liver Disease (NAFLD) involves fat accumulation in the liver without other causes, ranging from mild steatosis to severe inflammation and scarring, and its severity affects prognosis. This study evaluates the presence and resolution of liver fat accumulation in patients with active Cushing's Syndrome. Participants will undergo hepatic MRI scans and Fibroscan assessments to measure liver fat and fibrosis at diagnosis and one year after remission. The study involves an open-label approach with diagnostic tests to track changes in liver condition over two years. Participants will be monitored through imaging tests including hepatic MRI and Fibroscan to assess liver fat and fibrosis levels. Researchers will measure the frequency of complete resolution of hepatic steatosis over two years, along with various non-invasive biomarkers to evaluate liver health. Safety and follow-up will continue throughout the study period, which lasts up to two years from diagnosis.

NAC- NAFLD and Cushing